CAR-T Meeting 2021 | Supporting patients through CAR T-cell therapy
Lorna Warwick
• 8 Feb 2021
Lorna Warwick, Lymphoma Coalition, Toronto, Canada, shares her highlights from the group discussion on the ethics of CAR T-cell therapy. Ms Warwick reveals that although CAR T-cell therapy works well and results in lasting remissions for just over 40% of patients, we still don’t know how to predict which patients it will work best for. Therefore, it is important to inform patients about realistic outcomes and ensure patients have a team ready to support them through the process. In addition, Ms Warwick discusses the role of patient organizations in educating and supporting patients through CAR T-cell therapy. This interview took place during the 3rd European CAR T-cell Meeting.
